Entrada Therapeutics (TRDA) FCF Margin (2023 - 2025)
Historic FCF Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 1743.62%.
- Entrada Therapeutics' FCF Margin fell 16163600.0% to 1743.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 210.98%, marking a year-over-year decrease of 2028700.0%. This contributed to the annual value of 21.21% for FY2024, which is 1252300.0% down from last year.
- Per Entrada Therapeutics' latest filing, its FCF Margin stood at 1743.62% for Q3 2025, which was down 16163600.0% from 1526.36% recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' FCF Margin ranged from a high of 798.62% in Q1 2023 and a low of 1743.62% during Q3 2025
- For the 3-year period, Entrada Therapeutics' FCF Margin averaged around 286.73%, with its median value being 86.21% (2024).
- As far as peak fluctuations go, Entrada Therapeutics' FCF Margin soared by 2424600bps in 2024, and later tumbled by -16163600bps in 2025.
- Over the past 3 years, Entrada Therapeutics' FCF Margin (Quarter) stood at 11.92% in 2023, then plummeted by -623bps to 86.21% in 2024, then crashed by -1923bps to 1743.62% in 2025.
- Its last three reported values are 1743.62% in Q3 2025, 1526.36% for Q2 2025, and 192.87% during Q1 2025.